Amgen Inc. Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers Amgen Inc.'s Form 10-Q for the quarterly period ended June 30, 2026. Amgen operates as a single segment focused on human therapeutics, discovering, developing, and delivering innovative medicines. The company is a large accelerated filer with 540.6 million shares of common stock outstanding as of July 30, 2026.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenues | $10,054 | $9,179 | $18,672 | $17,328 |
| Product Sales | $9,537 | $8,771 | $17,755 | $16,644 |
| Operating Income | $3,514 | $2,656 | $6,180 | $3,834 |
| Net Income | $2,375 | $1,432 | $4,194 | $3,162 |
| Diluted EPS | $4.37 | $2.65 | $7.71 | $5.84 |
| Operating Cash Flow (6mo) | $6,191 | $3,671 | $6,191 | $3,671 |
| Cash & Equivalents (End Period) | $13,989 | $8,028 | $13,989 | $8,028 |
| Total Debt (Carrying Value) | $57,304 | $54,604 | $57,304 | $54,604 |
Margins (Q2 2026): Operating margin was 35.0% (up from 29.0% in Q2 2025). The effective tax rate was 14.2% for the quarter and 13.6% for the six-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10% in Q2 and 8% for the six months ended June 30, 2026, compared to the prior year. Product sales grew 9% in Q2, driven primarily by volume growth.
- Profitability: Net income surged 66% in Q2 and 33% for the six-month period. This was driven by higher operating income (up 32% in Q2) and lower amortization expenses from acquisition-related assets.
- Product Performance:
- Repatha: Sales increased 37% (Q2) and 35% (6mo) due to volume growth.
- EVENITY: Sales increased 38% (Q2) and 33% (6mo) driven by volume.
- UPLIZNA: Sales increased 90% (Q2) and over 100% (6mo) driven by volume.
- IMDELLTRA/IMDYLLTRA: Sales increased over 100% (Q2 and 6mo) driven by volume.
- Prolia: Sales declined 32% (Q2) and 33% (6mo) due to biosimilar competition and lower net selling prices.
- Otezla: Sales declined 21% (Q2) and 13% (6mo) due to lower net selling prices and generic competition in ROW.
- ENBREL: Sales declined 4% (Q2) and 19% (6mo) due to Medicare Part D price setting under the IRA.
- Investments: Unrealized losses on the BeOne Medicines Ltd. equity investment were $227 million in Q2 and $357 million for the six months, compared to gains in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects volume growth from certain brands to be partially offset by net selling price declines for the remainder of 2026. Capital expenditures for full-year 2026 are estimated at approximately $2.6 billion.
- Regulatory Risks (TAVNEOS): The FDA proposed to withdraw approval of TAVNEOS in April 2026 citing lack of substantial evidence of effectiveness and potential untrue statements in the original application. Amgen requested a hearing and submitted additional data. The product remains on the market during the process, but the outcome is uncertain.
- Tax Litigation: Amgen is contesting IRS Notices of Deficiency for tax years 2010–2015, which could result in additional federal taxes of approximately $8.7 billion plus interest and penalties. A decision from the U.S. Tax Court is expected no earlier than late 2026 or early 2027. Additionally, a draft Notice of Proposed Adjustment (NOPA) for years 2016–2018 was received in April 2026.
- Pricing Policy: The company is navigating the Inflation Reduction Act (IRA), Most-Favored-Nation (MFN) pricing initiatives, and the "One Big Beautiful Bill Act" (OB3). ENBREL is subject to Medicare price setting starting Jan 1, 2026, and Otezla starting Jan 1, 2027.
- Dividends: The Board declared a quarterly cash dividend of $2.52 per share for Q3 2026, payable in September 2026.
Key Facts for Investor Verification
- TAVNEOS Regulatory Status: Verify the outcome of the FDA hearing request regarding the proposed withdrawal of TAVNEOS approval and its potential impact on future revenue and intangible asset impairment.
- IRS Tax Dispute Resolution: Monitor the U.S. Tax Court decision on the 2010–2015 tax years and the status of the 2016–2018 NOPA, as adverse outcomes could materially impact financial statements.
- Biosimilar Erosion: Track the rate of sales decline for Prolia and XGEVA as biosimilar competition intensifies in the U.S. and ROW following patent expirations.
- IRA and MFN Impact: Assess the long-term financial impact of Medicare price setting on ENBREL and Otezla, and the broader implications of MFN pricing agreements on net selling prices.
- BeOne Investment Volatility: Review the fair value fluctuations of the BeOne Medicines Ltd. equity investment, which significantly impacted "Other (expense) income, net."